HairDX introduces improved genetic baldness test, incorporates maternal and paternal influences

NewsGuard 100/100 Score

HairDX, developer of the first genetic test for predicting the risk of male and female pattern hair loss (Androgenetic Alopecia) today announced it is now able to provide doctors with an improved prediction by looking at genetic variants inherited from the mother combined with the risk for baldness attributed by the father.

“A man whose father has even a minimal amount of hair loss who tests positive for the variant AR gene has over 80% chance of developing male pattern hair loss”

“It is well known in the medical community that pattern hair loss is inherited in a complex fashion with paternal as well as maternal influence. While the maternal inheritance of certain gene variants are necessary for the development of pattern hair loss, they are not sufficient. The HairDX test has improved predictive power by incorporating both maternal as well as paternal influences,” says Sharon Keene, M.D. Chief Medical Officer of HairDX.

“A man whose father has even a minimal amount of hair loss who tests positive for the variant AR gene has over 80% chance of developing male pattern hair loss,” says Andy Goren, President and CEO of HairDX.

The news is better for men whose fathers did not experience balding. A man whose father has no signs of hair loss who tests negative for the variant AR gene has over 90% chance of not developing male pattern hair loss.

“With the improved predictive value of the HairDX genetic test, a doctor is better informed than ever before, and can provide a personalised analysis of an individual’s likelihood of developing Androgenetic Alopecia, the most common type of hair loss,” said Goren.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study findings better define the genetic landscape of neuroendocrine tumors of the cervix